2Friedman M and Hilleman DE.Economic burden of chronic obstructive pulmonary disease:Impact of new treatment options.Pharmacoeconomics,2000,19:245-254.
3Mahler DA,Donohue JF,Barbee RA,et al.Efficacy of salmeterol xinafoate in the treatment of COPD.Chest,1999,115:957-965.
4Mahon JL,Laupacis A,Hodder RV,et al.Theophyline for irreversible chronic airflow limitation:a randomized study comparingn of 1 trials to standard practice.Chest,1999,115:38-48.
5Vestbo J,Sorensen T,Lange P,et al.Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease:a randomised controlled trial.Lancet,1999,353:1819-1823.
6Pauwels RA,Lofdahl CG,Laitinen LA,et al.Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking.European Respiratory Society study on chronic obstructive pulmonary disease.N Engl J Med,1999,340:1948-1953.
7Burge PS.EUROSCOP,ISOLDE and the Copenhagen city lung study[editorial].Thorax,1999,54:287-288.
8Friedman M,Serby C,Menjoge S,et al.Pharmoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD.Chest,1999,115:635-641.
9Campbell S.For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base.Arch Intern Med,1999,159:156-160.
8Demirel H,Demir T,Umut S.Retrospective evaluation of patient compliance in continuous oxygen therapy[J].Respiration,2003,70(2):149-153.
9Pepin JL,Barjhoux CE,Deschaux C.Long-term oxygen therapy at home:Compliance with medical prescription and effective use of therapy[J].Chest,1996,109(5):1144-1150.
10Morrison D,Skwarski K,Macnee W.Review of the prescription of domiciliary long term oxygen therapy in Scotland[J].Thorax,1995,50(10):1103-1105.
